SGS 742

Drug Profile

SGS 742

Alternative Names: CGP-36742; DVD-742; Lu-AE58479; SGS-742

Latest Information Update: 29 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Developer Lundbeck A/S; Novartis
  • Class Antidementias; Antiepileptic drugs; Nootropics; Organophosphorus compounds
  • Mechanism of Action GABA B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Epilepsy; Mild cognitive impairment

Most Recent Events

  • 13 Dec 2005 Data presented at the 35th Annual Meeting of the Society of Neuroscience (SfN-2005) have been added to the Alzheimer's Disease pharmacodynamics section
  • 22 Mar 2005 Phase-II clinical trials in Attention-deficit hyperactivity disorder in USA (PO)
  • 10 May 2004 Data presented at the 56th Annual Meeting of the American Academy of Neurology (AAN-2004) have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top